Display Settings:


Send to:

Choose Destination
Clin Chest Med. 2006 Mar;27(1 Suppl 1):S27-35, vi.

Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.

Author information

  • Lung Transplant and Advanced Lung Disease Program, Inova Heart and Vascular Institute, 3300 Gallows Road, Falls Church, VA 22042, USA. steven.nathan@inova.com


The treatment of idiopathic pulmonary fibrosis (IPF) remains controversial. The benefits of conventional treatment with corticosteroids plus either azathioprine or cyclophosphamide have not been established in randomized, controlled trials. Other treatment strategies have been suggested as understanding of the pathogenesis of IPF has increased. Recent clinical and animal studies suggest that modulating the effects of profibrotic growth factors and cytokines holds significant promise. As additional well controlled prospective studies are completed, these trials should provide the clinical evidence necessary for identifying optimal treatment strategies for future patients who have IPF.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk